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Background: Acinetobacter baumannii has a greater clinical impact and exhibits higher 
antimicrobial resistance rates than the non-baumannii Acinetobacter species. Therefore, 
the correct identification of Acinetobacter species is clinically important. Matrix-assisted 
laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MS) has re-
cently become the method of choice for identifying bacterial species. The purpose of this 
study was to evaluate the ability of MALDI-TOF MS (Bruker Daltonics GmbH, Germany) in 
combination with an improved database to identify various Acinetobacter species. 
Methods: A total of 729 Acinetobacter clinical isolates were investigated, including 447 A. 
baumannii, 146 A. nosocomialis, 78 A. pittii, 18 A. ursingii, 9 A. bereziniae, 9 A. soli, 4 A. 
johnsonii, 4 A. radioresistens, 3 A. gyllenbergii, 3 A. haemolyticus, 2 A. lwoffii, 2 A. junii, 2 
A. venetianus, and 2 A. genomospecies 14TU. After 212 isolates were tested with the de-
fault Bruker database, the profiles of 63 additional Acinetobacter strains were added to 
the default database, and 517 isolates from 32 hospitals were assayed for validation. All 
strains in this study were confirmed by rpoB sequencing. 
Results: The addition of the 63 Acinetobacter strains’ profiles to the default Bruker data-
base increased the overall concordance rate between MALDI-TOF MS and rpoB sequenc-
ing from 69.8% (148/212) to 100.0% (517/517). Moreover, after library modification, all 
previously mismatched 64 Acinetobacter strains were correctly identified. 
Conclusions: MALDI-TOF MS enables the prompt and accurate identification of clinically 
significant Acinetobacter species when used with the improved database.
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INTRODUCTION
The Acinetobacter genus is composed of over 40 named spe-
cies and nine genomic species [1, 2]. Among these Acineto-
bacter species, Acinetobacter baumannii is the most clinically 
important pathogen because it is involved in nosocomial infec-
tions and often exhibits multidrug resistance, particularly to car-
bapenems [3-5]. Non-baumannii Acinetobacter species have 
been isolated from patients with bacteremia, endocarditis, and 
meningitis [6-8]. The clinical features and antibiotic susceptibili-
ties of A. baumannii are different from those of non-baumannii 
Acinetobacter species. A previous study on the clinical charac-
teristics of Acinetobacter infections found that no cases of infec-
tion with non-baumannii Acinetobacter species aggravated to 
Jeong S, et al.
Identification of Acinetobacter by MALDI-TOF MS
326  www.annlabmed.org http://dx.doi.org/10.3343/alm.2016.36.4.325
severe sepsis or septic shock [9]. The overall antimicrobial sus-
ceptibilities of non-baumannii Acinetobacter species have been 
much higher than those of A. baumannii. The median number 
of administered antibiotics was also lower in the non-baumannii 
group [9-11]. Therefore, the accurate identification of Acineto-
bacter species is clinically significant. 
The currently available phenotypic identification systems can-
not precisely distinguish Acinetobacter species. Since Acineto-
bacter species are phenotypically very similar, non-baumannii 
Acinetobacter species are often erroneously identified as A. 
baumannii, resulting in overestimation of the prevalence of A. 
baumannii [12, 13]. In contrast, several genotypic methods, de-
veloped to differentiate Acinetobacter species, have been more 
effective [14-16]. Among these methodologies, the 16S ribo-
somal RNA (rRNA) and RNA polymerase β-subunit (rpoB) gene 
sequencing approaches have been widely used. The most fairly 
accurate method for the identification of Acinetobacter species 
was suggested to be rpoB gene sequencing, because of the 
abundance of rpoB polymorphisms in these species [14, 16, 
17]. However, these molecular techniques are laborious, expen-
sive, and time-consuming, making them unsuitable for routine 
identification of Acinetobacter species in clinical laboratories [2]. 
Matrix-assisted laser desorption ionization-time of flight 
(MALDI-TOF) mass spectrometry (MS) has been progressively 
applied for the identification of diverse microorganisms such as 
bacteria, yeasts, and even mycobacteria in clinical microbiology 
laboratories [18, 19]. MALDI-TOF MS yields unique mass spec-
tral fingerprints of these microorganisms that can be compared 
with a database of established fingerprints, thus enabling accu-
rate identification [18]. This method is simple, fast, and cost-ef-
fective, requiring only small amounts of samples [20]. Although 
several studies have attempted to adapt MALDI-TOF MS for the 
identification of Acinetobacter species, MALDI-TOF MS was in-
sufficient for species-level identification of Acinetobacter be-
cause of limited databases [2, 20]. 
Therefore, we generated an improved database and evalu-
ated the ability of MALDI-TOF MS in conjunction with our new 
database to identify a broad range of clinical Acinetobacter spe-
cies, based on the results of rpoB sequencing.
METHODS
1. Bacterial isolates
A total of 729 Acinetobacter clinical isolates collected between 
January 2012 and May 2015 at 32 university hospitals in Korea 
were included in this study. The isolates were composed of 447 
A. baumannii, 146 A. nosocomialis, 78 A. pittii, 18 A. ursingii, 9 
A. bereziniae, 9 A. soli, 4 A. johnsonii, 4 A. radioresistens, 3 A. 
gyllenbergii, 3 A. haemolyticus, 2 A. lwoffii, 2 A. junii, 2 A. vene-
tianus, and 2 A. genomospecies 14TU. After 212 strains (28 A. 
baumannii, 110 A. nosocomialis, 55 A. pittii, 3 A. ursingii, 3 A. 
bereziniae, 3 A. soli, 2 A. johnsonii, 2 A. radioresistens, 1 A. gyl-
lenbergii, 1 A. haemolyticus, 1 A. lwoffii, 1 A. junii, 1 A. venetia-
nus, and 1 A. genomospecies 14TU) were tested with the de-
fault Bruker database, the profiles of 63 Acinetobacter strains 
(31 A. nosocomialis, 11 A. pittii, 6 A. bereziniae, 6 A. soli, 2 A. 
ursingii, 1 A. gyllenbergii, 1 A. haemolyticus, 2 A. junii, 1 A. ve-
netianus, and 2 A. genomospecies 14TU) were added to the 
database. The updated 63 Acinetobacter strains are presented 
in Fig. 1. The rpoB sequence of each of the updated 63 Aci-
netobacter strains showed more than 99.0% identity with that of 
the closest species. Additionally, 517 Acinetobacter isolates (419 
A. baumannii, 36 A. nosocomialis, 23 A. pittii, 15 A. ursingii, 6 
A. bereziniae, 6 A. soli, 2 A. johnsonii, 2 A. radioresistens, 2 A. 
gyllenbergii, 2 A. haemolyticus, 1 A. lwoffii, 1 A. junii, 1 A. vene-
tianus, and 1 A. genomospecies 14TU) were assayed for valida-
tion. These clinical isolates were deposited in the National Cul-
ture Collection for Pathogens, supervised by the Korean Centers 
for Disease Control and Prevention. All strains were stored at 
-80°C; well-isolated colonies were used for all experiments after 
growth on MacConkey agar for 12-24 hr at 37°C. 
2. Species identification of Acinetobacter isolates
Species were identified by using the Vitek 2 system (bioMe´rieux 
Vitek Inc., Hazelwood, MO, USA) and/or 16S rRNA and rpoB 
sequencing [14, 16]. These sequences were compared against 
sequence databases by using a Basic Local Alignment Search 
Tool (BLAST) (http://blast.ncbi.nlm.nih.gov/Blast) [20]. Additional 
PCR amplification of blaOXA-51 was conducted to confirm A. 
baumannii [21]. 
3. MALDI-TOF MS
1) Bacterial extraction
Samples were prepared as previously described [20]. A 1-μL 
sterile loop was used to transfer each colony into 300 μL of dis-
tilled water, after which 900 μL of absolute ethanol was added. 
The suspension was centrifuged at 12,000g for 2 min and the 
resultant supernatant was discarded. After the pellet was dried 
at room temperature, 50 μL of 70% formic acid (Sigma-Aldrich, 
St. Louis, MO, USA) was added. The mixture was vortexed vig-
orously to yield a homogeneous solution. Finally, 50 μL of aceto-
nitrile (Sigma-Aldrich) was added, and the mixture was centri-
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Fig. 1. Dendrogram of the protein signatures of the updated 63 Acinetobacter strains, derived from matrix-assisted laser desorption ioniza-
tion-time of flight mass spectrometry (MALDI-TOF-MS) data. A. bereziniae, A. soli, A. gyllenbergii, A. junii, A. venetianus, and A. genomo-
species 14TU that were not in the default Bruker database are presented. All distance values are relative and normalized to a maximal val-
ue of 1,000.
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fuged at 12,000g for 2 min.
2) Species identification of bacterial extracts
One microliter of each prepared bacterial extract was spotted 
onto a stainless steel target plate (Bruker Daltonics GmbH, 
Leipzig, Germany) and was dried at room temperature for 10 
min. Next, 1 μL of matrix solution (consisting of alpha-cyano-
4-hydroxycinnamic acid, absolute acetonitrile and trifluoroacetic 
acid) was placed onto the sample. The solution and sample 
were allowed to co-crystallize for 10 min at room temperature. 
The prepared samples were analyzed by using a MicroFlex LT 
mass spectrometer (Bruker Daltonics), which was operated us-
ing Flex control software (version 3.4; Bruker Daltonics). Cali-
bration was conducted by using the Bacterial Test Standard 
(Bruker Daltonics) as recommended by the manufacturer.
3) Data analysis
Each prepared sample was analyzed on a MALDI Biotyper RTC 
(version 3.1; Bruker Daltonics); mass spectra were evaluated 
with Flex control software (Bruker Daltonics). Each mass 
spectrum was searched against the default Bruker database 
and against the updated database. The log score identification 
criteria, originating in the alignment of peaks to the best matching 
reference data, were classified as follows: ≥2.3, highly probable 
species; between 2.0 and 2.3, secure genus and probable 
species; between 1.7 and 2.0, probable genus; and <1.7, non-
reliable identification. The dendrogram of the Acinetobacter 
isolates was constructed by using the correlation distance 
measurements and the average linkage algorithm settings of 
MALDI Biotyper3 (version 3.1; Bruker Daltonics).
4) Library modification
Samples were prepared by using a Standard ethanol/formic 
acid extraction protocol as described earlier. One microliter of 
bacterial extract from each of the 63 Acinetobacter strains was 
spotted eight times onto a stainless steel target plate (Bruker 
Daltonics) and was dried for 10 min at room temperature. One 
microliter of matrix solution was also spotted onto each pre-
pared sample. After drying at room temperature for 10 min, 
each spot was measured three times. The obtained 24 spectra 
were analyzed with Flex analysis software (version 3.4; Bruker 
Daltonics). Accurately determined mass spectra were uploaded 
into the MALDI Biotyper3 software (Bruker Daltonics) to create 
mean spectra (MSP) for Acinetobacter species according to the 
Biotyper MSP creation standard method. 
Table 1. Identification of Acinetobacter species and the associated log score values, obtained by using MALDI-TOF MS
Acinetobacter 
   species
Default bruker database Improved database*
2.3-3.0 2.0-2.3 1.7-2.0 <1.7 Total 2.3-3.0 2.0-2.3 1.7-2.0 <1.7 Total
A. baumannii 100.0 (22/22)† 100.0 (5/5) 100.0 (1/1) 0.0 (0/0) 100.0 (28/28) 100.0 (376/376) 100.0 (43/43) 0.0 (0/0) 0.0 (0/0) 100.0 (419/419)
A. nosocomialis 85.7 (12/14) 38.0 (19/50) 70.4 (19/27) 57.9 (11/19) 55.5 (61/110) 100.0 (36/36) 0.0 (0/0) 0.0 (0/0) 0.0 (0/0) 100.0 (36/36)
A. pittii 94.1 (16/17) 100.0 (22/22) 80.0 (8/10) 66.7 (4/6) 90.9 (50/55) 100.0 (19/19) 100.0 (4/4) 0.0 (0/0) 0.0 (0/0) 100.0 (23/23)
A. ursingii 100.0 (3/3) 0.0 (0/0) 0.0 (0/0) 0.0 (0/0) 100.0 (3/3) 100.0 (5/5) 100.0 (8/8) 100.0 (2/2) 0.0 (0/0) 100.0 (15/15)
A. bereziniae 0.0 (0/1) 0.0 (0/1) 0.0 (0/0) 0.0 (0/1) 0.0 (0/3) 100.0 (6/6) 0.0 (0/0) 0.0 (0/0) 0.0 (0/0) 100.0 (6/6)
A. soli 0.0 (0/0) 0.0 (0/0) 0.0 (0/2) 0.0 (0/1) 0.0 (0/3) 100.0 (2/2) 100.0 (3/3) 100.0 (1/1) 0.0 (0/0) 100.0 (6/6)
A. johnsonii 0.0 (0/0) 100.0 (2/2) 0.0 (0/0) 0.0 (0/0) 100.0 (2/2) 0.0 (0/0) 100.0 (2/2) 0.0 (0/0) 0.0 (0/0) 100.0 (2/2)
A. radioresistens 100.0 (1/1) 100.0 (1/1) 0.0 (0/0) 0.0 (0/0) 100.0 (2/2) 100.0 (1/1) 100.0 (1/1) 0.0 (0/0) 0.0 (0/0) 100.0 (2/2)
A. gyllenbergii 0.0 (0/0) 0.0 (0/1) 0.0 (0/0) 0.0 (0/0) 0.0 (0/1) 100.0 (1/1) 100.0 (1/1) 0.0 (0/0) 0.0 (0/0) 100.0 (2/2)
A. haemolyticus 0.0 (0/0) 100.0 (1/1) 0.0 (0/0) 0.0 (0/0) 100.0 (1/1) 100.0 (2/2) 0.0 (0/0) 0.0 (0/0) 0.0 (0/0) 100.0 (2/2)
A. lwoffii 100.0 (1/1) 0.0 (0/0) 0.0 (0/0) 0.0 (0/0) 100.0 (1/1) 100.0 (1/1) 0.0 (0/0) 0.0 (0/0) 0.0 (0/0) 100.0 (1/1)
A. junii 0.0 (0/1) 0.0 (0/0) 0.0 (0/0) 0.0 (0/0) 0.0 (0/1) 100.0 (1/1) 0.0 (0/0) 0.0 (0/0) 0.0 (0/0) 100.0 (1/1)
A. venetianus 0.0 (0/1) 0.0 (0/0) 0.0 (0/0) 0.0 (0/0) 0.0 (0/1) 100.0 (1/1) 0.0 (0/0) 0.0 (0/0) 0.0 (0/0) 100.0 (1/1)
A. genomospecies 
   14TU
0.0 (0/0) 0.0 (0/1) 0.0 (0/0) 0.0 (0/0) 0.0 (0/1) 0.0 (0/0) 100.0 (1/1) 0.0 (0/0) 0.0 (0/0) 100.0 (1/1)
Total (%) 90.2 (55/61) 59.5 (50/84) 70.0 (28/40) 55.6 (15/27) 69.8 (148/212) 100.0 (451/451) 100.0 (63/63) 100.0 (3/3) 0.0 (0/0) 100.0 (517/517)
*The improved database consisted of the default Bruker database with the addition of representative mass spectra from 63 Acinetobacter strains; †(Number 
of concordant results between MALDI-TOF MS and rpoB gene sequencing/Number of all studied isolates confirmed by sequencing).
Abbreviations: MALDI-TOF MS, matrix-assisted laser desorption ionization-time of flight mass spectrometry.
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RESULTS
The analyzed results with log score values are presented in Ta-
ble 1. The species identification, which was confirmed by rpoB 
and 16S rRNA sequencing, has shown that MALDI-TOF MS 
yielded 69.8% (148/212) accuracy of identification at the spe-
cies level with the default Bruker database and 100.0% 
(517/517) with the improved database for all of the studied iso-
lates. When a log score of 2.0 was set as the cut-off value for 
probable species identification, the concordance rate between 
MALDI-TOF MS and sequencing increased from 72.4% (105/ 
145) with the default Bruker database to 100.0% (514/514) with 
the improved database. Furthermore, if only the results of log 
score above 2.3 were included for reliable species identification, 
the concordance rate between MALDI-TOF MS and sequencing 
was elevated from 90.2% (55/61) with the default Bruker data-
base to 100.0% (451/451) with the improved database.
Among the 64 discordant results for species identification 
with the default Bruker database, 49 A. nosocomialis and 5 A. 
pittii were erroneously identified as A. baumannii. The other 3 A. 
bereziniae, 3 A. soli, 1 A. gyllenbergii, 1 A. junii, 1 A. venetia-
nus, and 1 A. genomospecies 14TU were misidentified as A. 
nosocomialis, A. baumannii, A. baylyi, A. gyllenbergii, or could 
not be identified by MALDI-TOF MS. In contrast, none of the 
517 Acinetobacter strains for validation were misidentified when 
they were searched against the improved database using 
MALDI-TOF MS. Furthermore, the proportion of scores above 
2.0 among the accurately identified isolates at the species level 
was 70.9% (105/148) using the default Bruker database, while 
the proportion was 99.4% when using improved database of 
MALDI-TOF MS (514/517). In particular, the proportion with log 
scores above 2.0 among the accurately identified A. nosocomia-
lis increased from 50.8% (31/61) to 100.0% (36/36), and that 
of A. pittii increased from 76.0% (38/50) to 100.0% (23/23). 
Representative mass spectra of 16 Acinetobacter species, 
generated by the Flex analysis (Bruker Daltonics), are presented 
in Fig. 2. In addition, a dendrogram was constructed by using 
63 updated isolates from the improved database (Fig. 1). A. 
bereziniae, A. soli, A. gyllenbergii, A. junii, A. venetianus, and A. 
genomospecies 14TU, which were not included in the default 
Bruker database, are present in the dendrogram. A dendro-
gram, consisting of A. baumannii, A. nosocomialis, and A. pittii 
in the improved database, is shown in Fig. 3. Cluster analysis 
indicated that the protein signatures from A. baumannii species 
comprised a separate cluster, except those from A. baumannii 
CS 62_1 BRB, and were more closely related to those from A. 
nosocomialis than those from A. pittii. 
DISCUSSION
MALDI-TOF MS has been effective in identifying a broad spec-
trum of microorganisms, including bacteria, yeasts, and molds 
[18, 19]. However, identification rates for Acinetobacter species 
have been suboptimal; only 72.4% (89/123) of studied Acineto-
bacter isolates were accurately identified [2]. In the present 
study, 72.4% (105/145) of Acinetobacter strains were validly 
identified at the species level if a log score of 2.0 was set as the 
cut-off value with the default Bruker database. 
Most of the 64 discordant results consisted of 49 A. nosoco-
mialis and 5 A. pittii, which were misidentified as A. baumannii 
by MALDI-TOF MS. Insufficient A. nosocomialis and A. pittii-
specific protein signatures in the default Bruker database is one 
potential explanation for these identification failures. Kishii et al. 
[2] reported that the sensitivity improved from 74.8% to 82.4% 
after updating the default database with A. nosocomialis and A. 
pittii signatures. Additionally, 98.3% (59/60) of Acinetobacter 
isolates were identified at the species level, by using a local da-
tabase that incorporated the specific signature profiles for A. 
nosocomialis into the default Bruker database, according to the 
process described by Espinal et al. [20]. In the present study, 
the overall concordance rate between MALDI-TOF MS and rpoB 
sequencing for the identification of Acinetobacter species was 
substantially increased from 69.8% (148/212) to 100.0% 
(517/517) after more diverse representative signatures were in-
cluded within the default database. 
Of particular note, all of the A. nosocomialis (36/36) and A. 
pittii (19/19) isolates were successfully identified after including 
a wide range of A. nosocomialis and A. pittii mass spectra into 
the default database. Moreover, database modification in-
creased the proportion of scores above 2.0 among the correctly 
identified isolates from 70.9% (105/148) to 99.4% (514/517), 
further indicating the reliability of our results. 
Three A. bereziniae, three A. soli, one A. gyllenbergii, one A. 
junii, one A. venetianus, and one A. genomospecies 14TU iso-
lates were identified by MALDI-TOF MS after the incorporation 
of their protein signatures into the default Bruker database. 
These species could not previously be properly identified be-
cause of their absence in the default library. Kishii et al. [2] also 
correctly identified A. bereziniae and A. soli by MALDI-TOF MS, 
which had been misidentified as A. guillouiae and A. baylyi, af-
ter updating their original library.
Although the dendrogram showed that A. baumannii and A. 
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Fig. 2. Peak profiles of 15 representative Acinetobacter species generated by matrix-assisted laser desorption ionization-time of flight mass 
spectrometry (MALDI-TOF MS). The mass-to-charge (m/z) ratios of the ions are shown on the x-axis, and the absolute intensities of the ions 
are presented on the y-axis. AU values were given by the software.
Abbreviation: AU, arbitrary intensity. 
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Fig. 3. Dendrogram constructed from the specific matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-
MS)-generated mass spectra of A. baumannii, A. nosocomialis, and A. pittii within the improved database (which includes the original 
Bruker database). The protein profiles from A. baumannii isolates formed a separate cluster. The A. baumannii protein profiles were more 
closely associated with those from A. nosocomialis than those from A. pittii. All relative distance values are normalized to a maximal value of 
1,000.
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nosocomialis were more closely related to each other than to 
other Acinetobacter species, these two species obviously formed 
separate clusters and MALDI-TOF MS analysis enabled the un-
ambiguous identification of these two strains.
Peak analysis of representative Acinetobacter species yielded 
sufficient differences among their protein signatures for accu-
rate MALDI-TOF MS-based identification. In the present study, 
the 5,749.1 m/z peak for A. baumannii; the 4,070.5 m/z and 
8,139.0 m/z peaks for A. nosocomialis; and the 2,891.8 m/z, 
4,412.6 m/z, and 5,760.0 m/z peaks for A. pittii were specific 
and similar to those reported in previous studies. Hsueh et al. 
[22] found that the 2,875.03 m/z and 5,749.51 m/z peaks were 
specific for A. baumannii; the 4,070.04 m/z and 8,137.58 m/z 
peaks were specific for A. nosocomialis; and the 2,889.87 m/z, 
4,412.56 m/z, and 5,779.52 m/z peaks were specific for A. pit-
tii. Šedo et al. [23] also reported that the 5,748 m/z peak was 
specific for A. baumannii.
The clinical relevance of non-baumannii Acinetobacter has 
been shown to differ substantially from that of A. baumannii [1]. 
Non-baumannii Acinetobacter species tend to be less prevalent 
than A. baumannii, although the prevalence of each Acineto-
bacter species may differ geographically. The majority of noso-
comial Acinetobacter species isolated from patients during a 
3-yr surveillance program were identified as A. baumannii 
(84.5%), whereas only 5.6% of infections were caused by A. 
pittii [24]. Turton et al. [12] also reported that most isolates were 
identified as A. baumannii (78%) among 690 Acinetobacter 
strains, whereas the incidences of A. lwoffii, A. ursingii, and A. 
pittii were 8.8%, 4%, and 1.7%, respectively. Our Acinetobacter 
isolates for validation consisted of 81.0% A. baumannii (419/ 
517), 7.0% A. nosocomialis (36/517), and 4.4% A. pittii (23/ 
517) strains, a finding that is consistent with previous results. 
The first group of 212 Acinetobacter species was mainly used 
for the verification of non-baumannii Acinetobacter species, 
which had been erroneously identified by MALDI-TOF MS. On 
the other hand, the second group, which consisted of 517 Aci-
netobacter species, was randomly collected specifically for the 
purpose of validating the improved database, and is therefore, a 
more descriptive of the prevalence of Acinetobacter species. 
The limitation of the present study was the use of two separate 
groups with differing strain distributions and numbers in evalu-
ating the default and improved databases. A study analyzing the 
same groups with both the default and improved databases 
concurrently would provide a more accurate assessment of Aci-
netobacter prevalence. 
With respect to clinical characteristics, A. baumannii has pre-
dominantly accounted for nosocomial infection outbreaks in in-
tensive care units (ICU), although A. nosocomialis, A. pittii, and 
A. ursingii have also caused outbreaks [25-27]. The rates of 
ICU admissions (15.4% vs. 50.0%), hospital-acquired infec-
tions (76.9% vs. 97.2%), and mortality (16.7% vs. 58.6%) were 
significantly greater in the A. baumannii group than in the non-
A. baumannii group [9, 11]. Moreover, Park et al. [28] found 
that A. baumannii infection was an independent predictor of 
mortality in patients with Acinetobacter bacteremia, a finding 
that further emphasizes the importance of correct species iden-
tification of Acinetobacter species. 
Further, the antimicrobial susceptibilities of non-baumannii 
Acinetobacter species have been shown to differ greatly from 
those of A. baumannii. The resistance rates of A. nosocomialis 
and A. pittii to imipenem have been found to be 31% (4/13) 
and 6.7% (1/15), respectively, while that of A. baumannii was 
66% (35/53) [29]. The overall rates of imipenem and/or me-
ropenem resistance of the non-baumannii Acinetobacter iso-
lates was 2.6% according to a previous report [14]. These dif-
ferences likely originate from the different carbapenemases ex-
pressed by A. baumannii versus non-A. baumannii species [1]. 
Of particular interest, A. baumannii intrinsically harbors blaOXA-51, 
which can be used to differentiate A. baumannii from other Aci-
netobacter species. Additionally, Lee et al. [30] found that non-
baumannii Acinetobacter isolates were more resistant to colistin 
than A. baumannii. Colistin has been widely used to treat A. 
baumannii infections; however, A. genomospecies 14TU is in-
trinsically resistant to colistin [31]. 
Taken together, accurate identification of Acinetobacter spe-
cies is essential for appropriate management, which influences 
clinical outcomes. We demonstrated that refining the default 
MALDI-TOF MS database enabled the rapid and correct identi-
fication of Acinetobacter strains at the species level, thereby 
demonstrating the potential of this approach as an alternative to 
the use of laborious genotypic tools. In the present study, A. 
nosocomialis and A. pittii were the two most prevalent species 
after A. baumannii. These two species could be differentiated 
by MALDI-TOF MS by incorporating more diverse A. nosocomi-
alis and A. pittii mass spectra. A. bereziniae, A. soli, A. gyllen-
bergii, A. junii, A. venetianus, and A. genomospecies 14TU 
were also identified after the default library was complemented 
with their missing protein signatures. Furthermore, to the best of 
our knowledge, this is the first demonstration of the correct 
identification of A. gyllenbergii, A. venetianus, and A. genomo-
species 14TU clinical isolates by MALDI-TOF MS. Although this 
study could not include all of the Acinetobacter species nor a 
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sufficient number of strains of rare Acinetobacter species, our 
data indicate that Acinetobacter species isolated in the clinical 
settings could be correctly identified. Moreover, the present 
study included a wide range of clinical isolates from various uni-
versity hospitals, likely reflecting the diversity of species submit-
ted to actual clinical laboratories. 
In conclusion, our study showed that MALDI-TOF MS is an 
efficient technique for the accurate and rapid identification of 
Acinetobacter strains at the species level after library modifica-
tion. The updated database, achieved by inclusion of more di-
verse and specific protein signatures for each Acinetobacter 
species into the default Bruker library, is required for correct 
species identification. The misidentification of clinical Acineto-
bacter isolates could lead to significant outcomes such as ag-
gravation of infection or even death, given that the clinical rele-
vance and antimicrobial susceptibilities of these species differ 
greatly. Therefore, MALDI-TOF MS has the potential to become 
an essential technique, by which clinical microbiology laborato-
ries routinely identify Acinetobacter species.
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